T
Tibet Duo Rui Pharmaceutical Co Ltd
SZSE:301075
Tibet Duo Rui Pharmaceutical Co Ltd
SZSE:301075
Price:
63.3
CNY
-1.05%
Market Cap:
¥5.1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
T
|
Tibet Duo Rui Pharmaceutical Co Ltd
SZSE:301075
|
CN |
Multiples-Based Value
The Multiples-Based Value of one Tibet Duo Rui Pharmaceutical Co Ltd stock under the Base Case scenario is 8.43 CNY. Compared to the current market price of 63.3 CNY, Tibet Duo Rui Pharmaceutical Co Ltd is Overvalued by 87%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Multiples-Based Value
Base Case
8.43
CNY
Overvaluation 87%
T
Multiples Across Competitors
Competitors Multiples
Tibet Duo Rui Pharmaceutical Co Ltd Competitors
Tibet Duo Rui Pharmaceutical Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
T
|
Tibet Duo Rui Pharmaceutical Co Ltd
SZSE:301075
|
5B CNY | 28.2 | -39.9 | -33.1 | -33.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
902.5B USD | 13.8 | 43.7 | 29.5 | 31.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
581.1B USD | 6.2 | 21.7 | 15.1 | 18.5 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236.9B GBP | 5.3 | 30.7 | 16.9 | 23.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.4 | 11.5 | 13 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
303.6B USD | 4.7 | 16.6 | 10.3 | 12.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
232.5B CHF | 5.2 | 20.9 | 12.9 | 16.6 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.8B USD | 2.5 | 19.9 | 7.7 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.7B USD | 2.5 | 17 | 7.2 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
